Eli Lilly Reports 45% Revenue Growth to $12.73 Billion in Latest Quarter

Eli Lilly and Company reported significant financial growth in its latest quarterly results, with total revenue reaching $12.73 billion for the three months ended March 31, 2025, a 45% increase from $8.77 billion in the same period last year. The company's net income also rose by 23% to $2.76 billion, compared to $2.24 billion in the prior year. Earnings per share increased to $3.06, up from $2.48, reflecting the company's strong performance driven by higher sales volumes, particularly from its key products Mounjaro and Zepbound.

The substantial revenue growth was attributed to a 53% increase in volume, although this was partially offset by a 6% decline in realized prices and a 2% unfavorable impact from foreign exchange rates. Notably, Mounjaro's revenue surged by 113% year-over-year, while Zepbound generated $2.31 billion in the U.S. alone, a significant increase from $517.4 million in the previous year. The company also recognized a one-time benefit of $370 million related to its collaboration with Boehringer Ingelheim for the Jardiance product family.

In terms of operational developments, Eli Lilly's total assets increased to $89.39 billion as of March 31, 2025, up from $78.71 billion at the end of 2024. The company reported a rise in its employee headcount, reflecting ongoing investments in research and development, which totaled $2.73 billion for the quarter, an 8% increase from the previous year. Additionally, the company incurred $1.57 billion in acquired in-process research and development charges, primarily related to the acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.

Looking ahead, Eli Lilly anticipates continued growth driven by its expanding product portfolio and ongoing clinical trials. The company is focused on addressing the challenges posed by pricing pressures and regulatory changes, particularly in light of the Inflation Reduction Act, which may affect pricing strategies for certain drugs. Eli Lilly remains committed to investing in its research and development pipeline to sustain its competitive edge in the pharmaceutical market. The company has also initiated a $15 billion share repurchase program, with $13.8 billion remaining as of the end of the quarter, indicating confidence in its financial position and future prospects.